Home
Home
  • Home
  • About Us About Us
    • Overview
    • Who we are
    • Why we provide advice
    • What are health technologies
    • Meetings
    • News
    • Who we work with
    • Contact Us
  • What We Do What We Do
    • Overview
    • Our Strategy
    • Work programme
    • Range of advice products
    • Quarterly Bulletin of advice
    • Early HTA Advice Service
  • Our Advice
  • Request Advice Request Advice
    • Overview
    • Form for requesting advice
  • Get Involved Get Involved
    • Overview
    • Contribute to advice
    • NHS boards
    • Patient and Public Involvement
    • Industry Involvement
    • Observe a council meeting
    • DOI Form

Advice Statement

  • Home
  • Our Advice
  • Clinically stable rheumatoid arthritis - musculoskeletal ultrasound

Title

Output Type

Speciality

Published

Title

Clinically stable rheumatoid arthritis - musculoskeletal ultrasound

Output Type

Advice Statement

Speciality

Musculoskeletal system

Published

22 September 2017

Recommendation for NHSScotland

  • A meta-analysis based on seven observational studies suggests that MSUS is clinically effective in predicting relapse or progression of joint damage in rheumatoid arthritis patients in clinical remission.
  • Evidence from three additional primary studies suggests that MSUS can effectively identify rheumatoid arthritis patients in clinical remission who are suitable for tapering or stopping treatment, and can be used to monitor these patients for relapse.
  • No evidence was identified on the cost effectiveness of MSUS in rheumatoid arthritis patients in clinical remission.

NHSScotland is required to consider the Scottish Health Technologies Group (SHTG) advice.

What were we asked to look at?

In patients with clinically stable rheumatoid arthritis (clinical remission), can musculoskeletal ultrasound in addition to clinical examination detect or rule out inflammation that predicts subsequent joint damage to inform tapering and stopping treatment?

Why is this important?

With an increasing older population in Scotland the prevalence of rheumatoid arthritis is expected to increase. Advances in treatments for rheumatoid arthritis have made clinical remission a realistic therapeutic goal, with up to 40% of patients achieving remission status within six months of initiating treatment. With remission rates increasing, and concerns over the safety and cost of long-term treatment, there is growing interest in tapering or stopping treatment in rheumatoid arthritis patients achieving clinical remission. Musculoskeletal ultrasound (MSUS) is a rapid, non-radioactive method of imaging which could potentially inform decisions on tapering or stopping treatment in rheumatoid arthritis patients in remission.

Referred by

The Scottish Society for Rheumatology.

Download icon
Download Advice
pdf (368 KB)
Download icon
Download Plain Language Summary
pdf (333 KB)
Download icon
Download Evidence Note
pdf (682 KB)

Connect with Us

Please let us know if you'd like to receive regular updates on our work.


Last Updated: 5 August 2021

Scottish Health Technologies Group

© 2021, All rights reserved

  • Accessibility
  • Respecting your privacy
  • Cookies
  • Healthcare Improvement Scotland Website
  • Find us on Twitter
  • Freedom of Information

Tell us what you think


We'd love to hear your views

Was our advice useful?  Did you find what you were looking for on our website?